Untreated patients with stage IIIB/IV disease with NSCLC and a performance status of 0/1 were randomly assigned ( 1:1 ) to receive 100 mg/m ( 2 ) nab-P weekly plus C ( under the curve = 6 , every 3 weeks ) or 200 mg/m ( 2 ) sb-P plus C ( under the curve = 6 ) every 3 weeks .